Volume 26, Number 7—July 2020
Dispatch
Laboratory-Acquired Dengue Virus Infection, United States, 2018
Tyler M. Sharp, Teresa G. Fisher, Kristin Long, Garry Coulson, Freddy A. Medina, Carolyn Herzig, Mary Beth Koza, Jorge Muñoz-Jordán, Gabriela Paz-Bailey, Zack Moore, and Carl Williams
Table
Summary of diagnostic test results of serum specimens collected from a case-patient with laboratory-acquired DENV infection, United States, 2018*
| Specimen designation | Time of specimen collection† | rRT-PCR | NS1 ELISA | IgM ELISA | DENV IgG ELISA titer | Neutralizing antibody titer |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DENV-1 | DENV-2 | DENV-3 | DENV-4 | WNV | YFV | ||||||
| Baseline‡ | −1.5 y | NT | NT | NT | 1:40 | <20 | <20 | <20 | <20 | <20 | 40 |
| Acute‡ | 7 d | Neg | Pos | Pos | 1:163,840 | <80 | 160 | 640 | 640 | <80 | 160 |
| Early convalescent‡ | 28 d | NT | NT | Pos | 1:163,840 | 80 | 640 | 1280 | 320 | 40 | 80 |
| Late convalescent§ | 190 d | NT | NT | Pos | 1:40,960 | 40 | <20 | 160 | 160 | NT | NT |
*DENV, dengue virus; IgM ELISA, anti-DENV IgM antibody capture enzyme linked immunosorbent assay; NS1 ELISA, nonstructural protein 1 ELISA; NT, not tested; rRT-PCR, real-time reverse transcription PCR; WNV, West Nile virus; YFV, yellow fever virus.
†Relative to illness onset.
‡Neutralizing antibody titers obtained by 90% plaque reduction neutralization test.
§Neutralizing antibody titers obtained by recombinant microfluorescence reduction neutralization test.
Page created: April 30, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential